Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Medical Oncology Service, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Future Oncol. 2022 Jun;18(20):2475-2481. doi: 10.2217/fon-2021-1609. Epub 2022 May 10.
Adenosquamous carcinoma of the pancreas (ASCP) is a very rare and highly aggressive variant of pancreatic ductal adenocarcinoma, accounting for 0.5-4% of all pancreatic cancer cases in the USA. Current data indicate that epigenetic changes and overexpression lead to squamous transdifferentiation of pancreatic tumor cells and development of ASCP. Minnelide™, an oral anti-super-enhancer drug that inhibits expression in preclinical models of ASCP, has demonstrated safety in a phase I study. We describe the design for a phase II, open-label, single-arm trial of Minnelide in patients with advanced refractory ASCP.
胰腺腺鳞癌（ASCP）是一种非常罕见且高度侵袭性的胰腺导管腺癌变体，占美国所有胰腺癌病例的 0.5-4%。目前的数据表明，表观遗传改变和过表达导致胰腺肿瘤细胞的鳞状转化，并发展为 ASCP。Minnelide™是一种口服抗超级增强子药物，在 ASCP 的临床前模型中抑制表达，在一项 I 期研究中显示出安全性。我们描述了一项 Minnelide 治疗晚期难治性 ASCP 患者的 II 期、开放标签、单臂试验的设计。
